Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2004

View Archived Issues

Oral agents effective against murine cytomegalovirus in vivo

Promising liver-selective thyromimetic for the treatment of hepatocellular carcinoma

Three series of antibacterial oxazolidinones patented by Pfizer

Novel chemokine CCR2B antagonists identified at Janssen

New metal-chelating alphavbeta3 integrin antagonists and their use

GSK researchers describe new SGK-1 inhibitors and their use

Novel phospholipase A2 inhibitors in early development at Merckle

New antibacterial oxazolidinones under evaluation at Ranbaxy

Positive preliminary results from second phase III trial of CDP-870 in RA

Anticancer compound WX-671 enters clinical development

New intravenous formulation of MC-1 gives positive phase I results

Phase III clinical trials of Aquavan commence

Phase III trial for Ceplene fails to meet primary endpoint

Vicuron provides update on the NDA status of anidulafungin

Antiinflammatory and therapeutic effects of ciclesonide in asthma

Viral-specific immune responses induced with multiple-epitope vaccines for HIV-1 and SIV

DOR BioPharma completes a pivotal trial with orBec in GvHD

4SC and Mutabilis collaborate to identify new molecules against infectious diseases

PD-332991 enters phase I

Extended Aranesp dosing approved by European Commission

Tarceva plus gemcitabine combination improves survival in pancreatic cancer patients

The EMEA accepts marketing authorization application for Macugen

IDM cleared to begin U.S. phase II trial of Uvidem

ISTA Pharmaceuticals' Vitrase granted three-year market exclusivity

Prasterone active in systemic lupus erythematosus

Insight into mechanism of action of analgesic GR-242468

Business plans at Savient

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.